Improving healing of the cornea using new chemical compounds
Chemical Optimization of c-Cbl Antagonists for Corneal Wound Healing
This study is looking at new treatments that could help heal the surface of the eye more quickly and effectively for people with corneal damage, by using a special compound to boost the healing process.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project ID | NIH-10557187 on NIH RePORTER |
What this research studies
This research focuses on developing new compounds that can enhance the healing of the corneal epithelium, which is crucial for maintaining vision and protecting the eye from infections. The researchers aim to chemically optimize a specific antagonist that affects the epidermal growth factor receptor (EGFR) to promote cell migration, proliferation, and differentiation in the cornea. By preventing the degradation of EGFR, the study seeks to prolong its activity, thereby improving the restoration of corneal tissue after injury. Patients with corneal damage may benefit from these new treatments that could lead to faster and more effective healing.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with corneal epithelial damage due to trauma, disease, or side effects from medications.
Not a fit: Patients with intact corneal epithelium or those with conditions unrelated to corneal healing may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new therapeutic options for patients suffering from corneal injuries, potentially reducing recovery time and improving vision.
How similar studies have performed: While the approach of optimizing c-Cbl antagonists is relatively novel, similar strategies targeting EGFR signaling have shown promise in other areas of tissue healing.
Where this research is happening
Louisville, United States
- University of Louisville — Louisville, United States (Active)
Researchers
- Principal investigator: Ceresa, Brian P. — University of Louisville
- Study coordinator: Ceresa, Brian P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.